Advertisement Australia to subsidize cervical cancer immunization program - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Australia to subsidize cervical cancer immunization program

Biological products company CSL has said that the Australian government will make Merck & Co.'s cervical cancer Gardasil available to school girls aged 12 to 18 years under a new government-funded National Immunization Program.

As part of the scheme, a free vaccine program for women aged 19-26 will also be delivered by doctors.

CSL said that the immunization program will commence in 2007. The Australian government expects to spend a total of $436 million on the purchase of the vaccine over a four year period.

Originally a government advisory committee rejected a request by CSL to subsidize Gardasil, claiming that the three-shot course was too expensive.

Cervical cancer kills about 250,000 women annually, making it the second-biggest cause of death among female cancer patients globally, according to the World Health Organization.

“The combination of a national immunization program with Gardasil, and regular two yearly pap semars means that we could substantially reduce the burden of cervical cancer and pre-cancers,” said Dr Brian McNamee CEO of CSL.